"The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin "...
SYLATRON is contraindicated in patients with:
- A history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b
- autoimmune hepatitis
- hepatic decompensation (Child-Pugh score > 6 [class B and C])
Last reviewed on RxList: 12/4/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Sylatron Information
Sylatron - User Reviews
Sylatron User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get the latest treatment options.